Business & Finance
Bavarian Nordic sells US Priority Review Voucher for USD160m
18 June 2025 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday that it has agreed to sell its US Priority Review Voucher for a total cash consideration of USD160m....
Bavarian Nordic sells US Priority Review Voucher for USD160m
18 June 2025 - Denmark-based vaccines company Bavarian Nordic A/S (CPH:BAVA) announced on Wednesday that it has agreed to sell its US Priority Review Voucher for a total cash consideration of USD160m....
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
12 June 2025 - Critical care and infectious disease specialist Innoviva Specialty Therapeutics Inc (IST), a subsidiary of Innoviva Inc (Nasdaq:INVA), announced on Thursday that the US Food and Drug Ad...
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
2 June 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Monday that it has entered into an agreement to acquire Blueprint Medicines Corporation (NASDAQ:BPMC)...
Eisai forecasts 73% Leqembi revenue growth in FY 2025, boosting BioArctic royalties
15 May 2025 - Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) reported on Thursday that its partner Eisai Co Ltd (TYO:4523) projects Leqembi (lecanemab) revenue to reach JPY76.5bn (...
ValiRx subsidiary Inaphaea extends drug repurposing deal with Dominion Biotech
12 May 2025 - ValiRx plc (AIM: VAL), a specialist in early-stage cancer therapeutics and women's health, reported on Monday that it has extended a commercial agreement between its wholly owned su...